First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

Item

http://www.wikidata.org/entity/Q47763039

Q47763039

about

HER2-positive breast cancer is lost in translation: time for patient-centered research.Mechanisms and Therapy for Cancer Metastasis to the Brain.Lung cancer in never smokers-the East Asian experience

P2860

Q38648765-AB93D253-4D8C-4854-BE0C-BA51A7B0E4F6 Q54950354-CBEF0D59-9F06-442B-9C88-DE35A11B2193 Q58804388-B2965B10-485F-4D5E-8A15-2DDBEC5E01AD

P2860

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

Item

http://www.wikidata.org/entity/Q47763039

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

First-line icotinib versus cis ...... open-label, randomized study.

@en

First-line icotinib versus cis ...... open-label, randomized study.

@nl

type

Item

label

First-line icotinib versus cis ...... open-label, randomized study.

@en

First-line icotinib versus cis ...... open-label, randomized study.

@nl

prefLabel

First-line icotinib versus cis ...... open-label, randomized study.

@en

First-line icotinib versus cis ...... open-label, randomized study.

@nl

P1476

First-line icotinib versus cis ...... open-label, randomized study.

@en

P2093

B H Han

http://www.w3.org/2001/XMLSchema#string

C M Ding

http://www.w3.org/2001/XMLSchema#string

C Yao

http://www.w3.org/2001/XMLSchema#string

F L Tan

http://www.w3.org/2001/XMLSchema#string

G Y Chen

http://www.w3.org/2001/XMLSchema#string

H L Zhang

http://www.w3.org/2001/XMLSchema#string

J F Feng

http://www.w3.org/2001/XMLSchema#string

K Li

http://www.w3.org/2001/XMLSchema#string

L M Ding

http://www.w3.org/2001/XMLSchema#string

L Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Cancer statistics, 2016

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Epidermal growth factor receptor mutations in lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

P304

2443-2450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX359

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28945850

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

about

P2860

P2860

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921